Insider Selling: Joao Md Siffert Sells 21,094 Shares of Avanir Pharmaceuticals Stock (AVNR)
Avanir Pharmaceuticals (NASDAQ:AVNR) SVP Joao Md Siffert sold 21,094 shares of Avanir Pharmaceuticals stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $4.22, for a total value of $89,016.68. Following the completion of the transaction, the senior vice president now directly owns 116,200 shares in the company. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of analysts have recently weighed in on AVNR shares. Analysts at Wedbush reiterated an “outperform” rating on shares of Avanir Pharmaceuticals (NASDAQ:AVNR) in a research note to investors on Thursday, September 12th. Separately, analysts at Piper Jaffray Cos. reiterated an “overweight” rating on shares of Avanir Pharmaceuticals (NASDAQ:AVNR) in a research note to investors on Monday, August 26th. They now have a $13.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Avanir Pharmaceuticals (NASDAQ:AVNR) from $3.00 to $4.50 in a research note to investors on Wednesday, August 7th.
Five research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $11.30.
Shares of Avanir Pharmaceuticals (NASDAQ:AVNR) traded up 1.41% during mid-day trading on Thursday, hitting $4.33. The stock had a trading volume of 1,934,925 shares. Avanir Pharmaceuticals has a 52 week low of $2.07 and a 52 week high of $6.00. The stock’s 50-day moving average is $4.9 and its 200-day moving average is $3.91. The company’s market cap is $629.9 million. Avanir Pharmaceuticals also was the target of some unusual options trading on Monday. Stock traders purchased 7,348 put options on the stock. This is an increase of approximately 352% compared to the typical volume of 1,625 put options.
Avanir Pharmaceuticals (NASDAQ:AVNR) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.11) by $0.03. The company had revenue of $19.80 million for the quarter, compared to the consensus estimate of $19.53 million. During the same quarter last year, the company posted ($0.11) earnings per share. Avanir Pharmaceuticals’s revenue was up 88.6% compared to the same quarter last year. Analysts expect that Avanir Pharmaceuticals will post $-0.38 EPS for the current fiscal year.
AVANIR Pharmaceuticals, Inc (NASDAQ:AVNR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.